The clinical information you need, at your fingertips.

Once-daily oral daraxonrasib significantly improves overall survival and progression-free survival vs. chemotherapy in previously treated patients. . .

Among patients eligible for short‑course therapy (~10%), outcomes were similar with 3 to 4 vs. 5 or more days of antibiotics. . .

Tuberculosis DNA was detected in a notable share of hospitalized U.S. patients who would not typically be considered for a TB diagnosis. . .

Nearly half (49.6%) of health‑related responses from widely used AI chatbots were rated somewhat or highly problematic, with frequent misinformation and incomplete guidance. . .

A large U.S. cohort study finds no evidence that community water fluoridation is associated with lower IQ in adolescence or cognitive decline later in life. . .

New findings show GLP-1 signaling directly improves liver inflammation and fibrosis independent of body weight change. . .

Regulator cites insufficient evidence to support approval of Replimune’s oncolytic immunotherapy combination. . .

Updated approval allows continued treatment beyond six months for macular edema due to retinal vein occlusion. . .

Aligning exercise timing with a person’s natural “morning” or “evening” preference led to greater improvements in blood pressure, fitness, and sleep than exercising at mismatched times. . .